Back to Results
First PageMeta Content
Bevacizumab / Ranibizumab / Angiology / Macular degeneration / Pharmaceutical industry / Vascular endothelial growth factor / Directorate-General for Health and Consumers / Committee for Medicinal Products for Human Use / Consumer organization / Medicine / Congress of Deputies / Health


Avastin vs Lucentis Letter sent to Vice-President Almunia on March 17th, 2014 Contact: Ilaria Passarani – [removed] Ref.: BEUC-X[removed]/2014
Add to Reading List

Document Date: 2014-03-18 12:19:39

Open Document

File Size: 266,81 KB

Share Result on Facebook

City

Brussels / /

Company

Novartis / Roche / Lucentis Dear / /

Continent

Europe / /

Currency

EUR / /

/

/

IndustryTerm

pharmaceutical products / pharmaceutical / healthcare systems / /

Organization

European Medicines Agency / European Consumer Organisation / European Commission / Italian National Health Service / European Union / European Medicine Agency Committee / Italian Authority / BEUC Italian / /

Person

Altroconsumo / Paola Testori-Coggi / Almunia / Alexander Italianer / DG SANCO / Ilaria Passarani / /

/

Position

vp / Vice-President / Director General / /

Product

Avastin / Lucentis / /

ProgrammingLanguage

EC / /

URL

www.beuc.eu / www.twitter.com/beuctweet / http /

SocialTag